Chronic Interstitial Lung Diseases in Children: Diagnosis Approaches
Chronic Interstitial Lung Diseases in Children: Diagnosis Approaches
Chronic Interstitial Lung Diseases in Children: Diagnosis Approaches
To cite this article: Nadia Nathan, Laura Berdah, Keren Borensztajn & Annick Clement (2018):
Chronic interstitial lung diseases in children: diagnosis approaches, Expert Review of Respiratory
Medicine, DOI: 10.1080/17476348.2018.1538795
Article views: 2
DOI: 10.1080/17476348.2018.1538795
Chronic interstitial lung diseases in children: diagnosis approaches
t
ip
1. Service de pneumologie pédiatrique, Centre national de référence des maladies
respiratoires rares RespiRare, Hôpital Armand Trousseau, Assistance Publique Hôpitaux
cr
de Paris (AP-HP), Paris 75012, Fr.
2. Sorbonne Université and Inserm UMRS933, Paris 75012, Fr.
us
Corresponding author
an
Nadia Nathan
Pediatric Pulmonology Department
M
Sorbonne Université and Hôpital Trousseau AP-HP
26 avenue du Dr Arnold Netter, 75012-Paris, Fr.
ed
Tel : +33(1) 44 73 66 18
Fax : +33(1) 44 73 67 18
nadia.nathan@aphp.fr
pt
ce
Ac
Abstract
t
ip
Areas covered: This review provides an update on chILD pathophysiology and diagnosis
approaches in immunocompetent children. It includes current information on genetic causes.
cr
Expert commentary: ChILD covers a large spectrum of entities with heterogeneous disease
us
expression. Various classifications have been reported, but none of them seems completely
satisfactory. Recently, progress in molecular genetics has allowed identifying some genetic
contributors, with, so far, a lack of correlations between gene disorders and disease
an
expression. Despite improvements in patient management, chILD prognosis is still burdened
by significant morbidity and mortality. Ongoing international collaborations will allow
M
gathering larger longitudinal cohorts of patients to improve disease knowledge and
personalized care. The overall goal is to help the children with ILD to reach the adulthood
transition in a better condition, and to structure genetic counseling for their family.
ed
pt
Key words
Pediatric interstitial lung disease, chILD, diagnosis approach, classification, genetics,
ce
surfactant
Ac
Introduction
t
defect and/or impaired gas exchange [1].
ip
1. Definition and classification
cr
2.1 Definition
us
The lung interstitium is a support tissue and is composed of 3 parts: the axial interstitium for
the bronchovascular tree, the parenchymal interstitium for the pulmonary parenchyma
an
structure, and the peripheral interstitial for the component adjacent to the pleura [2]. Diseases
of the lung interstitium are usually designated as ILD, a term that is not correct as, in most
M
situations, the pathological processes do not affect exclusively the support tissues of the
respiratory system. The term of diffuse lung diseases offers a better designation of these
disorders, which can involve the alveolar structure as well as the distal part of the small
ed
airways and the conducting zone, i.e. the terminal bronchioles. In keeping with the generally
disease designation in clinical practice, the term ILD will be used in the present review, with
pt
the understanding that it refers to disorders that affect the respiratory function of the lung and
consequently the pulmonary structure responsible of the diffusion of gases between blood and
ce
air (i.e. the alveolar epithelium, the interstitium, and the pulmonary capillary endothelium)
[3,4].
Ac
2.2 Classification
Many different approaches have been used for the classification of ILD, with major shifts
observed over time based on improvements in clinical investigation tools which include chest
imaging and close collaboration with pathologists. In adult patients, initial descriptions were
histopathological, with proposed 4 distinct subgroups: usual interstitial pneumonia,
desquamative interstitial pneumonia (DIP) and a closely related pattern termed respiratory
bronchiolitis-associated interstitial lung disease, acute interstitial pneumonia (formerly
Hamman-Rich syndrome), and non-specific interstitial pneumonia (NSIP). Progressively, this
historical gold standard has been replaced by a multi-disciplinary approach that has led to
define 7 specific entities and to provide standardized terminology and diagnostic criteria. This
approach resulted in an international multidisciplinary consensus classification of interstitial
pneumonias published in 2002 by the American Thoracic Society (ATS) / European
Respiratory Society (ERS) that was updated in 2013 [5,6]. The strategies developed for adult
ILD classification were similarly used for children ILD (chILD), with initially mainly
histologic descriptions [7]. Progressively, multi-disciplinary classification schemes that
t
ip
include patient age and clinical situations were set up, providing the basis for clinico-
radiologic-pathologic diagnosis [8,9]. Patient age is clearly an important issue as the cellular
cr
and molecular events associated with the ongoing lung growth and maturation processes are
known to interfere with the clinical expression of the pathological disorders [10].
us
Consequently, the chILD research cooperative group and the European (EU)-chILD
collaboration network have individualized the ILD more prevalent in children less than 2 yr
an
old, and the ILD not specific to children age [8]. ILD observed mainly during infancy include
developmental disorders and growth abnormalities, neuroendocrine cell hyperplasia, and
pulmonary interstitial glycogenesis [11,12]. The other pediatric ILD can be grouped into: ILD
M
2.3 Epidemiology
Estimated prevalence reported in several studies showed large variations that range from 0.1
pt
to 16.2 cases per 100,000. These numbers are difficult to ascertain and may be under-
ce
estimated due to the lack of standardized definitions, the differences in the studied patient
populations, and the absence of organized reporting systems. From the limited published data
composed mainly of case reports and small series, it seems that pediatric ILD occur more
Ac
frequently in the younger age and in boys. In addition, nearly 10 % of cases would be familial
[18–20].
t
ip
during feeding (in young children) and weight loss are common symptoms in young children
[3,8]. A history of wheezing may be observed [22]. The frequent clinical findings are
cr
tachypnea, inspiratory crackles and retraction. Other findings associated with an advanced
stage of lung disease include finger clubbing and cyanosis during exercise or at rest.
us
Thorough physical examination includes the search for respiratory and non-respiratory
manifestations such as joint pain, cutaneous rashes and recurrent fever suggestive of
an
underlying systemic diseases.
Chest imaging is an important component of disease diagnosis. Plain radiographs are usually
performed in a child suspected of ILD at first presentation, but the information provided is
ed
often limited and the key tool for diagnosis is the high resolution computed tomography
(HRCT), which can visualize the parenchymal structure to the level of the secondary
pulmonary lobule. HRCT technique for ILD diagnosis has been extensively discussed. To
pt
optimise spatial resolution, there is a general agreement to use thin sections, the smallest field
ce
of view and a sharp resolution algorithm [23]. The most common HRCT feature of ILD is
widespread ground-glass attenuation. Intralobular lines, irregular interlobular septal
thickening and honeycombing are less common findings. Large subpleural air cysts in the
Ac
upper lobes adjacent to areas of ground-glass opacities have been also reported in young
children with ILD. These cysts are interpreted as paraseptal or irregular emphysema. HRCT is
useful for ILD diagnosis but is most of the time insufficient to determine the ILD aetiology.
Consequently, in most situations, diagnosis investigations including molecular studies and
lung tissue analysis are warranted. In this context, HRCT is helpful to guide the selection of
lung area to be biopsied. It is proposed that it also may contribute to monitor disease
progression [24–28]. However, evaluation is still needed to support a role of HRCT as a
follow up tool in pediatric patients. Recently, the use of magnetic resonance imaging in the
follow-up of pediatric ILD is being discussed, and much effort is currently being engaged to
significantly improve image quality [29].
t
ip
(VC) is variably diminished; the decrease in total lung capacity (TLC) in general is relatively
less than in VC. Functional residual capacity (FRC) is also reduced but relatively less than
cr
VC and TLC, and residual volume (RV) is generally preserved; thus, the ratios of FRC/TLC
and RV/TLC are often increased. Airway involvement is observed only in a minority of
us
patients. Lung diffusing capacity of carbon monoxide (DLCO) or transfer factor (TLCO) is
often markedly reduced and may be abnormal before any radiological findings. Hypoxemia as
an
defined by a reduced resting arterial oxygen saturation (SaO2) or a reduced resting arterial
oxygen tension is often present. Hypercarbia occurs only late in the disease course. During
exercise the above described dysfunctions become even more pronounced. Thus, gas
M
exchange during exercise might be a more consistent and sensitive indicator of early disease
[1,8].
ed
and distal parenchyma. It provides specimen for cytological microbiologic and molecular
ce
studies; its primary usefulness is to search for infections. It may also orient the diagnosis in
situations of alveolar hemorrhage, alveolar proteinosis, or aspiration with lipid-laden
macrophages [30].
Ac
Lung biopsy and histological investigations are important investigations, in line with
increasing recognition of the different patterns of ILD and their clinical significance.
However, it is critical to take into consideration that they are invasive [31]. Consequently, as
reported by the European consortium for chILD, histological evaluation of lung tissue usually
represents the final step of a series of diagnostic approaches [8]. The methods used to obtain
lung tissue, should balance their invasiveness against the potential for obtaining adequate and
sufficient tissue for diagnosis. The techniques of choice are open lung biopsy and video
assisted thoracoscopy biopsy. The place of other methods such as transbronchial lung biopsy
and percutaneous needle lung biopsy remains to be established in pediatric ILD. Samples
should be fixed for light microscopy (staining, immunohistochemistry), but also prepared in
Glutaraldehyde-buffer for electronic microscopy (EM) and frozen for eventual molecular
genetics analyses [8,32]. The lung histological patterns which can be observed in pediatric
ILD include mainly: DIP, NSIP, and lymphocytic interstitial pneumonia (LIP). DIP is
characterized by airspaces filled with alveolar macrophages, thickened alveolar septa,
scattered mixed inflammatory cells and minimal fibrosis. Many alveolar spaces are lined by
hyperplastic type 2 alveolar epithelial cells (AEC). As example, surfactant disorders have
t
ip
reported to be associated with a DIP pattern on light microscopy and to dense lamellar bodies
aspects on EM analysis [33]. NSIP encompasses a broad spectrum of abnormalities with
cr
varying degrees of alveolar wall inflammation or fibrosis. The cellular pattern of NSIP is
characterized by mild to moderate interstitial chronic inflammation and type 2 AEC
us
hyperplasia in inflammation areas. It has been reported in a variety of underlying conditions
including connective tissues diseases and surfactant disorders. LIP features include a marked
an
diffuse infiltrate of mature lymphocytes, plasma cells and histiocytes within the pulmonary
interstitium, particularly the alveolar walls. They are often associated with either connective
tissues disorders or immunodeficiency states, both congenital and acquired [7,14]. EM
M
Based on the clinical context, other investigations could be proposed at patient presentation.
ce
situation.
A large number of pathological situations can impair gas exchange and contribute to
progressive lung damage and ILD. Consequently, diagnosis approaches need to be organized
by cause, with a clinical evaluation requiring a careful history paying attention to exposures
and systemic diseases. Indeed, from a number of reports it is noteworthy that lung insults
caused by substances from the environment or in the context of systemic diseases are largely
under-estimated and should be more often considered in the diagnostic process. Importantly,
information on relatives or siblings with similar lung conditions are critical and should be
thoroughly gathered. Accordingly, once the diagnosis of ILD is established on clinical,
radiological, and functional findings, a step-by-step etiological diagnostic approach is
required [1]. Numerous ILD classifications have been reported. In the present review, we
chose to use a clinical approach as diagnostic strategy, with the various pediatric ILD
gathered into 4 groups: ILD related to exposure/environment insults, ILD related to systemic
t
ip
diseases processes, ILD related to primary lung parenchyma dysfunctions, and ILD specific to
infancy (Table 1).
cr
4.1 ILD related to exposure/environment insults
us
They refer to diseases caused by a critical dose of exposure to components with the lung,
inducing clinical manifestations and biological impairments. The adult literature has provided
an
extensive lists of involved and candidate molecules. In children, less is known about the
potential lung involvement of these molecules. It is important to stress out that pediatric
exposure-related diseases is certainly under-estimated as the diagnosis is less often discussed
M
than in adults [35,36]. Indeed, pediatricians and other child health care providers do not
usually have the expertise necessary to retrace an environmental history that has to take into
ed
account the home environment but also the daycare, playgrounds, hobbies of the pediatric
patient [37].
Hypersensitivity pneumonitis (HP) is a cell-mediated immune reaction to inhaled antigens in
pt
susceptible persons. The responsible antigens have to be searched first in the home
ce
environment as well as in relation to certain hobbies. HP are often diagnosed in children at the
chronic stage of the disease resulting of a long-term exposure to low levels of inhaled
antigens. Children can develop inflammatory reactions in the lung without noticeable
Ac
symptoms for months. The classical clinical presentation includes non-productive cough,
dyspnea, malaise, asthenia and occasional cyanosis [38]. The most frequent types of HP
include bird fancier’s diseases, humidifier lung diseases, and chemical lung diseases. Bird
fancier’s diseases, or bird breeder’s disease are induced by exposure to birds antigens mainly
from avian droppings and feathers [39,40]. The disease can occur shortly after the onset of the
exposure, or more often after a chronic exposure. Importantly, a suspicion of HP should be
raised in case of respiratory symptoms in exposed patients who have only one pet bird at
home. Humidifier lung diseases, as well as air conditioner lung, misting fountain lung,
basement lung diseases and hot tube lung are caused mainly by free-living amoeba and
nematodes, as well as bacteria and fungi [41,42]. Chemical lung diseases can be induced by
various inorganic antigens such as inhaled paints, plastics, wax, talcum etc... [43]. In all cases,
once exposure history is suspected, the intervention of an expert environment advisor is
mandated to assess the exposure and environmental measurements and biologic tests are
necessary to make the causal link between the ILD and the exposure. Serum-precipitating IgG
antibodies against the offending antigen will be searched for. However, even if presents, the
clinical relevance of the positivity of these antibodies has to be discussed as it is observed in
t
ip
up to 50% of serum samples of exposed but asymptomatic individuals. Overall, no diagnostic
tests are pathognomonic for HP, and only a compatible exposure history and a bundle of
cr
biological and radiological signs can be predictive for HP. BAL is neither specific of HP but
an alveolitis with a T CD8 lymphocytosis must evoke the diagnosis. Of importance, HP is
us
usually highly sensible to corticosteroids, and a quick and positive response to this treatment,
combined with a removal of the causal exposure, can be a supplemental tool for HP diagnosis.
an
Medications, radiations and drugs can also cause ILD. Drugs used in inflammatory or cancer
pediatric diseases can cause ILD. They include anti-inflammatory agents (e.g. aspirin,
etanercept), immunosuppressive and chemotherapeutic agents (e.g. azathioprine,
M
pathophysiology targeting the connective tissues of the body. In childhood, the main CTD
disorders involving the lung are rheumatoid arthritis, systemic sclerosis, systemic lupus
erythematosus. The other include Sjögren syndrome, dermatomyositis and polymyositis,
Ac
t
ip
that affect large/medium vessels (such as Kawasaki’s disease, polyarteritis nodosa) only
occasionally affect the lung.
cr
Granulomatous disorders are characterized by the presence of granulomas defined as a focal
aggregation of monocellular and giant cells surround by inflammatory cells. Granulomas
us
constitute the result of tissue injury that can be triggered by a variety of agents including
micro-organisms, antigens, chemical, drugs and other irritants. In other situations, including
an
sarcoidosis, the etiologic factors remain to be determined. Sarcoidosis is the most frequent
cause of granulomatous ILD. It is a chronic inflammatory disease that is supposed to be the
result of a genetic susceptibility, associated with environmental antigens that remain to be
M
identified [46]. The current concept is that a still unknown stimulus activates quiescent T cells
and macrophages leading to recruitment and activation of mononuclear cells, with, as a
ed
consequence, granuloma formation, alveolitis, and in some cases interstitial lung fibrosis. The
granuloma can develop in many organs, mainly the lung. In children, sarcoidosis is rare and
affects mostly black pre-teenagers. The diagnosis is based on a combination of suggestive
pt
the absence of other known causes of granuloma formation. The disease is often severe in
children, presenting as a multi-organic disorder with general symptoms at the forefront (fever,
asthenia). Clinical manifestations in sarcoidosis depend on the organ or system involved.
Ac
t
ip
"sea-blue histiocytes" on pathology [48]. Hermansky-Pudlak syndrome is a heterogeneous
group of autosomal recessive disorders associated with accumulation of a ceroid-like
cr
substance in lysosomes of a variety of tissues. It is characterized by albinism, bleeding
tendency associated to poor platelet aggregation, and systemic complications associated to
us
lysosomal dysfunction [49].
an
4.3 ILD related to primary lung parenchyma dysfunctions
This group share common histopathological description, with preserved pulmonary
architecture, hyperplasia of type 2 AEC, interstitial infiltrates composed of immune-
M
/inflammatory cells and scattered myofibroblasts, and the alveolar space filled with either
immuno/inflammatory cells, desquamated materials, or components derived from surfactant
ed
lipid and protein complex. They include mainly surfactant disorders, DAH, eosinophilic lung
disease, lymphatic disorders and lung infections. Surfactant disorders are reviewed in the next
section.
pt
DAH can be observed in various clinical situations with or without systemic diseases. In the
absence of systemic findings, isolated pulmonary capillaritis should be discussed with the
ce
search for positivity of the anti-glomerular basement membrane antibody with linear deposits
in the lung tissue biopsy as well as suggestive serologic features such as p-ANCA antibodies.
Ac
Cow’s milk allergy (Heiner’s syndrome) and diseases induced by environmental factors such
as pesticide should also be evocated. Idiopathic pulmonary hemosiderosis is a diagnosis of
exclusion based on patient presentation with acute, subacute, or recurrent DAH, on the results
of lung biopsy showing evidence of ‘bland’ pulmonary hemorrhage (ie, without capillaritis or
vasculitis), and after exclusion of the conditions listed above. In this situation, red blood cells
leak into the alveolar space without evidence of damage and/or inflammation of the alveolar
capillaries [50].
Eosinophilic lung diseases constitute a diverse group of disorders of various origins. The
diagnosis is suggested by the presence of pulmonary infiltrates on chest imaging and
peripheral eosinophilia. It is confirmed by the presence of increased amounts of eosinophils in
BAL and/or lung tissue eosinophilia. The search for an etiology includes a combination of
clinical and laboratory investigations. Eosinophilic lung diseases of known cause in children
include mainly allergic bronchopulmonary aspergillosis, parasitic infections and drug
reactions. Eosinophilic lung diseases of unknown cause comprise Loeffler syndrome
(characterized by migrating pulmonary opacities), acute eosinophilic pneumonia, and chronic
t
ip
eosinophilic pneumonia. The idiopathic hyper-eosinophilic syndrome is a rare disorder; it is
characterized by prolonged eosinophilia and a multiorgan system dysfunction due to
cr
eosinophil infiltration with pulmonary involvement documented in almost half of the patients
[51].
us
Lymphatic disorders can be classified as primary or secondary. Congenital errors of lymphatic
development can lead to primary pulmonary lymphatic disorders that include lymphangiomas
an
and lymphangiomatosis, lymphangiectasis, and lymphatic dysplasia syndrome (congenital,
yellow nail syndrome). Secondary forms of lung lymphatic disorders result from a variety of
processes such as chronic airway inflammation that impair lymph drainage and increase
M
a number of human and experimental reports. From recent knowledge, it is strongly suggested
that latent viral infections may be involved in the pathogenesis of ILD, through targeting of
the alveolar epithelium. The main virus implicated include adenovirus, members of herpes
pt
virus family human (Epstein-Barrr virus and cytomegalovirus), and respiratory syncitial virus.
ce
Number of other viruses can also be involved such as Influenza A, hepatitis C, or even
Human immunodeficiency virus in immunocompetent children.
Ac
t
ip
Pulmonary interstitial glycogenosis (PIG) is also a non-lethal disease of unknown
cr
pathogenesis, reported in neonates with respiratory distress syndrome developed shortly after
birth. Very few cases have been described so far but it seems to have a male preponderance.
us
The histological hallmark of PIG is the accumulation of monoparticulate glycogen in the
mesenchymal cells on lung biopsy. It is thought to represent a developmental cell disorder
an
that leads them to accumulate glycogen within their cytoplasm [60]. A histological PIG aspect
can be isolated or associated with other pathological conditions such as meconium inhalation,
other lung growth development anomalies, and cardiovascular diseases [34]. It is discussed
M
that PIG could meet “chronic pneumonitis in infancy” as this remains a generalized term.
Diffuse developmental disorders are severe and often lethal conditions [61]. Acinar dysplasia
ed
development of the lung with thickened interstitium, a poor capillary bed, and in most cases,
ce
the presence of pulmonary veins in the bronchovascular axis instead of at the periphery of the
lobule. The newborns present with refractory hypoxemia and severe pulmonary hypertension.
The diagnosis is usually made on autopsies. Recently, mutations in TBX4 and FGFR2 have
Ac
been associated with syndromic acinar dysplasia [62,63]. The majority of the described cases
of ACD/MPV have been found to be related to FOXF1 mutations or to mutations in the
FOXF1 enhancer. Extra-pulmonary disorders are documented in more than half of the cases:
congenital heart diseases, digestive malformations or malrotations, and genitourinary
malformations [64–66].
Other alveolar growth disorders may be linked to Filamin A defects. Filamin A is a ubiquitous
cytoskeletal protein interacting with actin. Mutations in FLNA have been associated with
dominant syndromic ILD. FLNA is located on the X chromosome and female have been more
described than male [67]. Chest imaging show marked emphysema of the lungs, lobular septal
thickening and diffuse patchy atelectasis [68]. In addition to lung manifestations,
periventricular nodular heterotopias, dental and dermal anomalies, heart diseases and
impaired psychomotor development and cognition are reported.
Genetic factors are important contributors to pediatric ILD. Genetic variations have been
t
ip
mainly described in genes encoding (or interacting with) the surfactant proteins (SP): SP-C
(SFTPC) and the ATP-binding cassette-family A-member 3 (ABCA3) (ABCA3), and less
cr
frequently in the genes encoding NKX homoeobox 2 (NKX2)-1, (NKX2-1), SP-B (SFTPB),
SP-A (SFTPA). In situations of pulmonary alveolar proteinosis (PAP), genetic variations in
us
genes encoding the methionyl-tRNA synthetase (MARS) (MARS) and the granulocyte-
macrophage colony-stimulating factor (GM-CSF) receptors (CSF2RA and CSF2RB) have
been reported [69].
an
5.1 Genetic disorders of SP metabolism
M
SFTPC mutations have been associated with various forms of ILD, with heterogeneous
clinical presentations from severe neonatal respiratory distress to children and adult ILD and
ed
lung fibrosis. SP-C is first produced as a pro-protein and then processed through several
proteolytic steps to a mature peptide of 35 amino acids (4 kDa). The inheritance pattern is
autosomal dominant, with incomplete penetrance and severity. Approximately, half of the
pt
mutations are de novo mutations. To date, more than 40 different mutations have been
reported [70–72]. One missense mutation, the c.218T>C (p.Ile73Thr) is reported in roughly
ce
Genetic ABCA3 disorders were first reported in a group of full term babies with severe
respiratory diseases occurring shortly after birth and with mostly rapid fatal outcome [77]. It
is now known that bi-allelic mutations can also be diagnosed in older children with ILD, and
in adult with fibrosing ILD. ABCA3 disorders include mainly hereditary deficiencies in an
autosomal recessive inheritance. However, heterozygous ABCA3 mutations have also been
associated with an increased risk of neonatal respiratory distress in late preterm newborns.
The increasing number of mutations documented in a heterozygous state suggests that ABCA3
defects may be the most common causes of inherited surfactant diseases [78]. To date, more
than 200 mutations have been reported in ABCA3, located on chromosome 16, with various
heterogeneous clinical expressions, even in siblings [79–81]. One variant, c.875A>T
(p.Glu292Val), observed in 0.4% of the general population, is found in 4% of a cohort of
infants with respiratory distress [82].
Lung disorder resulting from NKX2-1 dysfunction was first reported in an infant with
neonatal thyroid disease and respiratory failure [83]. It has since been associated with the
“brain-lung-thyroid” syndrome. The inheritance pattern is autosomal dominant, with
t
ip
incomplete penetrance and severity for each of the 3 involved organs, even in a single family
[84]. Approximately half of the mutations are de novo mutations. NKX2-1 is a transcription
cr
factor, located on chromosome 14, that promotes SFTPB, SFTPC and ABCA3 transcription in
the alveolar epithelial cells. To date, over 50 mutations have been described, with no recurrent
us
mutation identified [85].
an
SP-B deficiency was the first surfactant disorder to be described in 1993 in a full-term infant
with progressive and fatal respiratory failure [86]. Since this first report, other cases have
been reported; most of them being fatal despite aggressive treatments and mechanical
M
supports. However, few cases with late survival have also been described. The inheritance
pattern is autosomal recessive. SFTPB, is located on human chromosome 2. SP-B is first
ed
produced as a pro-protein and is then processed through proteolytic cleavages of the NH2 and
COOH termini to a mature peptide of 79 amino acids (8 kDa). Presently, more than 40
different mutations have been reported, with the frameshift mutation 121ins2, resulting in a
pt
premature termination codon, being found in approximately two thirds of cases [87,88].
ce
SP-A the most abundant SP, is a hydrophilic protein that belongs to the C-type lectin family
(collectines). The human SP-A locus consists of 2 functional genes: SFTPA1 and SFTPA2,
Ac
with a pseudo gene (SFTPA3) in between, on chromosome 10. After processing, SP-A1 and
SP-A2 assemble to a large multimeric octadecameric “bouquet-like” protein structure [89,90].
To date, mutations have been mainly documented in SFTPA2 in adult patients. The phenotype
associates various forms of fibrosing ILD, and adenocarcinoma of the lung [91–93]. Recently,
our group identified a germline mutation in SFTPA1 in a family with various forms of ILD in
an infant, in children and in adults, some of them also presenting with an adenocarcinoma of
the lung. The penetrance was incomplete [94].
5.2 Other genetic disorders
MARS deficiencies were first described in PAP by a whole exome sequencing (WES)
approach. The patients presented mostly severe and early forms of PAP, some of them being
associated with liver and brain involvement [95]. MARS is an ubiquitary enzyme that
catalyzes the ligation of methionine to tRNA. It is encoded by MARS, which is located on
chromosome 12. Less than 10 bi-allelic mutations have been reported in patients, most of
them being originated from La Reunion Island and carrying the same ancestral mutated allele.
To date, the relationship between the MARS mutations and the PAP phenotype is not clearly
t
ip
understood.
cr
Very rare cases of pediatric PAP have been associated with GM-CSF receptor defects [96,97].
The clinical presentation is heterogeneous, with patients being diagnosed in adulthood. The
us
effects of GM-CSF are mediated through heterodimeric cell surface receptors that are
expressed on a number of cell surfaces including macrophages, neutrophils and type 2 AEC.
an
The GM-CSF receptors are composed of α chains encoded by the CSF2RA gene and β chains
encoded by the CSF2RB gene. It is suggested that the GM-CSF receptor defect could be
responsible for a lack of efficiency of the alveolar macrophages in recycling the SP, that
M
Coatomer Protein (COP)-α (COPA) [98]. STING, a stimulator of interferon genes, plays an
ce
Pediatric ILD comprises a large spectrum of rare respiratory disorders, some of them being
more prevalent in either infants or older children. The age at onset and the disease expression
are highly heterogeneous. Several classifications have been proposed so far based on
histological descriptions and patient presentations. However, none of them appears to be
t
completely satisfactory. As such, surfactant molecular disorders have been recently described
ip
in NEHI patients. The development of molecular diagnosis, especially with the generalization
of next generation sequencing, allows to document genetic disorders in an increasing number
cr
of chILD [106]. In the next years, the classifications will include these novel findings on
underlying molecular mechanisms. Along with a better description of the pathologies, there is
us
an urgent need for more specific treatments and care. To date, the therapeutic managements of
most pediatric ILD remain limited and are mainly based of the use of corticosteroids.
an
However, their efficacy is highly variable, most likely due to the vast heterogeneity of the
diseases. New therapeutical strategies targeting specific molecular mechanisms are in
M
progress. They include the use of tyrosine kinase inhibitor or transforming growth factor
inhibitor in children. In addition, lung transplantation is being developed for pediatric
patients. So far, pediatric lung transplantation has been reported in a limited number of
ed
patients with surfactant disorders (SFTPB, SFTPC, ABCA3), SAVI and COPA syndrome, and
in a few cases of developmental disorders, but it remains an exceptional procedure available
pt
7. Five-year view
A better understanding of the pathophysiological mechanisms and the natural course of the
Ac
diseases is a crucial issue. The rarity of the diseases makes this goal a challenge that deserves
international clinical and scientific collaborations to gather large longitudinal cohorts of
patients, and to develop ongoing basic research. Recently, a European research group of
clinicians and researchers has been launched by the European Cooperation in Science and
Technology (COST) action (CA-1625) and is currently developing multidisciplinary
approaches on clinical issues and is exploring the various preclinical models of ILD. It will
provide new insights into the molecular / environmental basis of ILD pathogenesis (including
genetic factors causing familial diseases) in children. As such, it is expected that newly
identified molecular defects and markers will help predicting clinical courses and tailoring
individual therapies.
Key issues
• Interstitial lung disease (ILD) is a heterogeneous group of rare respiratory disorders that
include ILD related to exposure/environment insults, ILD related to systemic diseases
processes, ILD related to primary lung parenchyma dysfunctions, and ILD specific to
t
infancy.
ip
• Current chILD classifications remain unsatisfactory, due to the complexity of the
underling mechanisms and the variability of the disease expression.
cr
• ChILD are mostly severe diseases with high morbidity and mortality.
us
• Management strategies and therapeutic options remain limited.
• Genetic factors are important contributors to chILD pathogenesis, and it is anticipated that
genetic testing will have an important role in chILD clinical practice in the next years.
an
Surfactant disorders play important roles in the development of various forms of chILD.
In addition to surfactant genes, other disease-causing genes are increasingly implicated in
M
chILD pathogenesis.
• chILD phenotypic expression is highly variable and, currently, no correlations between
disease presentation and molecular defect could be documented.
ed
Acknowledgements
The authors would like to thank the Assistance Publique Hôpitaux de Paris, Sorbonne
Université, Paris, France, and the national networks for rare lung diseases: Centre de
Ac
référence des maladies respiratoires rares (RespiRare), Centre de référence des maladies
pulmonaires rares (OphaLung) and Filière de soins pour les maladies respiratoires rares
(RespiFIL). The ILD cohort is developed in collaboration with the Rare Cohort Disease
(RaDiCo)-ILD project (ANR-10-COHO-0003), the FP7-305653-child-EU project and the
COST Action European network for translational research in children's and adult interstitial
lung disease (COST-ILD) project (CA16125).
Funding
The authors’ work is supported by grants from the Institut National de la Santé et la
Recherche Médicale (INSERM), the Legs Poix from the Chancellerie des Universités (grants
2013 n°1305, 2014 n°1405, 2015 n°1015, 2016 n°2077 and 2017 n°DP2017/1860), Paris, the
European Union’s Seventh Framework Program (FP7-ChILD-EU 2007-2013) under grant
agreement n°305653, as well as funding from the patient organizations Respirer c’est Grandir
and Belleherbe Association.
Declaration of Interest
t
ip
The authors have no other relevant affiliations or financial involvement with any organization
or entity with a financial interest in or financial conflict with the subject matter or materials
cr
discussed in the manuscript apart from those disclosed.
Reviewers Disclosure
us
Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
an
Abbreviations
M
ABCA3 ATP-Binding Cassette-Family A-Member 3
ACD/MPV Alveolar Capillary Dysplasia/Misalignment of Pulmonary Veins
ed
t
ip
MARS Methionyl-t-rna Synthetase
NEHI NeuroEndocrine cell Hyperplasia of Infancy
cr
NKX2 NK2 Homeobox
NSIP Non-Specific Interstitial Pneumonia
us
PIG Pulmonary Interstitial Glycogenosis
RV Residual Volume
an
SaO2 Arterial Oxygen Saturation
SAVI STING-Associated Vasculopathie of Infancy
SP Surfactant Protein
M
Reference annotations
* Of interest
Ac
** Of considerable interest
[1] Clement A, Nathan N, Epaud R, et al. Interstitial lung diseases in children. Orphanet J Rare
Dis. 2010;5:22.
[2] Weibel E, Gil J. Structure-function relationships at the alveolar level. West JB, ad.
Bioengineering aspect ofthe/ung. Marcel Dekker. New York; 1977. p. 1–81.
[3] ** Kurland G, Deterding RR, Hagood JS, et al. An official American Thoracic Society clinical
practice guideline: classification, evaluation, and management of childhood interstitial lung disease in
infancy. Am. J. Respir. Crit. Care Med. 2013;188:376–394.
A major article on pediatric ILD.
[4] Rice A, Tran-Dang M-A, Bush A, et al. Diffuse lung disease in infancy and childhood:
expanding the chILD classification. Histopathology. 2013;63:743–755.
t
A major article on adult ILD.
ip
[6] ** Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic
cr
Society/European Respiratory Society statement: Update of the international multidisciplinary
classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–
us
748.
[9] Soares JJ, Deutsch GH, Moore PE, et al. Childhood interstitial lung diseases: an 18-year
retrospective analysis. Pediatrics. 2013;132:684–691.
pt
[10] Nathan N, Thouvenin G, Fauroux B, et al. Interstitial lung disease: physiopathology in the
context of lung growth. Paediatric Respiratory Reviews. 2011;12:216–222.
ce
[11] ** Nogee LM. Interstitial lung disease in newborns. Semin Fetal Neonatal Med.
2017;;22(4):227-233
Ac
[12] Spagnolo P, Bush A. Interstitial Lung Disease in Children Younger Than 2 Years. Pediatrics.
2016;137.
[13] ** Griese M, Seidl E, Hengst M, et al. International management platform for children’s
interstitial lung disease (chILD-EU). Thorax. 2018 Mar;73(3):231-239
The authors presented the first results of the European database dedicated to chILD. This was a
collaborative work of the chILD European consortium.
[14] Fan LL, Dishop MK, Galambos C, et al. Diffuse Lung Disease in Biopsied Children 2-18
Years of Age: Application of the chILD Classification Scheme. Ann Am Thorac Soc.
2015;12(10):1498-505
[15] Hime NJ, Zurynski Y, Fitzgerald D, et al. Childhood interstitial lung disease: A systematic
review. Pediatr. Pulmonol. 2015;50:1383–1392.
[16] Kuo CS, Young LR. Interstitial lung disease in children. Curr. Opin. Pediatr. 2014;26:320–
327.
[17] Vece TJ, Young LR. Update on Diffuse Lung Disease in Children. Chest. 2016;149:836–845.
t
[18] Dinwiddie R, Sharief N, Crawford O. Idiopathic interstitial pneumonitis in children: a national
ip
survey in the United Kingdom and Ireland. Pediatr Pulmonol. 2002;34:23–29.
[19] Nathan N, Taam RA, Epaud R, et al. A national internet-linked based database for pediatric
cr
interstitial lung diseases: the French network. Orphanet J. Rare Dis. 2012;7:40.
[20] Saddi V, Beggs S, Bennetts B, et al. Childhood interstitial lung diseases in immunocompetent
us
children in Australia and New Zealand: a decade’s experience. Orphanet J Rare Dis. 2017;12:133.
[21] ** Clement A, de Blic J, Epaud R, et al. Management of children with interstitial lung
an
diseases: the difficult issue of acute exacerbations. Eur. Respir. J. 2016;48:1559–1563.
A collaborative work of the chILD European consortium that established criteria to define acute
exacerbations in children with chILD, based on a DELPHI process.
M
[22] Bajaj S, Muranjan M, Karande S, et al. Rare disease heralded by pulmonary manifestations:
Avoiding pitfalls of an “asthma” label. J Postgrad Med. 2017;63:122–127.
ed
[24] * Semple TR, Ashworth MT, Owens CM. Interstitial Lung Disease in Children Made
Easier…Well, Almost. Radiographics. 2017;37:1679–1703.
ce
[25] Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children.
Ac
[26] Guillerman RP. Imaging of Childhood Interstitial Lung Disease. Pediatr Allergy Immunol
Pulmonol. 2010;23:43–68.
[27] Klusmann M, Owens C. HRCT in paediatric diffuse interstitial lung disease--a review for
2009. Pediatr Radiol. 2009;39 Suppl 3:471–481.
[29] Dournes G, Grodzki D, Macey J, et al. Quiet Submillimeter MR Imaging of the Lung Is
Feasible with a PETRA Sequence at 1.5 T. Radiology. 2015;276:258–265.
[30] Midulla F, Villani A, Merolla R, et al. Bronchoalveolar lavage studies in children without
parenchymal lung disease: cellular constituents and protein levels. Pediatr. Pulmonol. 1995;20:112–
118.
[31] Fortmann C, Schwerk N, Wetzke M, et al. Diagnostic accuracy and therapeutic relevance of
thoracoscopic lung biopsies in children. Pediatr. Pulmonol. 2018; 2018 Jul;53(7):948-953
[32] Langston C, Patterson K, Dishop MK, et al. A protocol for the handling of tissue obtained by
operative lung biopsy: recommendations of the chILD pathology co-operative group. Pediatr. Dev.
Pathol. 2006;9:173–180.
t
ip
[33] Edwards V, Cutz E, Viero S, et al. Ultrastructure of lamellar bodies in congenital surfactant
deficiency. Ultrastruct Pathol. 2005;29:503–509.
cr
[34] Canakis A-M, Cutz E, Manson D, et al. Pulmonary interstitial glycogenosis: a new variant of
neonatal interstitial lung disease. Am. J. Respir. Crit. Care Med. 2002;165:1557–1565.
us
[35] Fink JN, Ortega HG, Reynolds HY, et al. Needs and opportunities for research in
hypersensitivity pneumonitis. Am. J. Respir. Crit. Care Med. 2005;171:792–798.
[36]
an
Venkatesh P, Wild L. Hypersensitivity pneumonitis in children: clinical features, diagnosis,
and treatment. Paediatr Drugs. 2005;7:235–244.
[37] Charpin D, Baden R, Bex V, et al. Environmental home inspection services in Western
M
Europe. Environ Health Prev Med. 2011;16:73–79.
[39] Stauffer Ettlin M, Pache J-C, Renevey F, et al. Bird breeder’s disease: a rare diagnosis in
young children. Eur. J. Pediatr. 2006;165:55–61.
ce
[40] Nacar N, Kiper N, Yalcin E, et al. Hypersensitivity pneumonitis in children: pigeon breeder’s
disease. Ann Trop Paediatr. 2004;24:349–355.
[41] Yoon HM, Lee E, Lee JS, et al. Humidifier disinfectant-associated children’s interstitial lung
Ac
[42] Kim KW, Ahn K, Yang HJ, et al. Humidifier disinfectant-associated children’s interstitial lung
disease. Am. J. Respir. Crit. Care Med. 2014;189:48–56.
[43] Magon P. Reversible lung disease due to abundant use of talcum powder. Indian J Pediatr.
2012;79:1383.
[44] * Dell S, Cernelc-Kohan M, Hagood JS. Diffuse and interstitial lung disease and childhood
rheumatologic disorders. Curr Opin Rheumatol. 2012;24:530–540.
A review on rheumatologic related ILD.
[45] Tarantino G, Esposito S, Andreozzi L, et al. Lung Involvement in Children with Hereditary
Autoinflammatory Disorders. Int J Mol Sci. 2016;17.
[46] Calender A, Rollat Farnier PA, Buisson A, et al. Whole exome sequencing in three families
segregating a pediatric case of sarcoidosis. BMC Med Genomics. 2018;11:23.
[47] * Nathan N, Marcelo P, Houdouin V, et al. Lung sarcoidosis in children: update on disease
expression and management. Thorax. 2015;70:537–542.
t
A recent update and large experience on pediatric sarcoidosis.
ip
[48] Gülhan B, Ozçelik U, Gürakan F, et al. Different features of lung involvement in Niemann-
cr
Pick disease and Gaucher disease. Respir Med. 2012;106:1278–1285.
us
with fibrosing lung disease early in childhood. Orphanet J Rare Dis. 2018;13:42.
[50] * Taytard J, Nathan N, de Blic J, et al. New insights into pediatric idiopathic pulmonary
an
hemosiderosis: the French RespiRare(®) cohort. Orphanet J Rare Dis. 2013;8:161.
[52] Epaud R, Fauroux B, Boule M, et al. [Diseases of the pulmonary lymphatic system in
children]. Rev Pneumol Clin. 2003;59:7–15.
pt
[53] Young LR, Deutsch GH, Bokulic RE, et al. A mutation in TTF1/NKX2.1 is associated with
ce
[54] Nevel RJ, Garnett ET, Worrell JA, et al. Persistent Lung Disease in Adults with NKX2.1
Mutation and Familial Neuroendocrine Cell Hyperplasia of Infancy. Ann Am Thorac Soc.
Ac
2016;13:1299–1304.
[56] Rauch D, Wetzke M, Reu S, et al. Persistent Tachypnea of Infancy. Usual and Aberrant. Am.
J. Respir. Crit. Care Med. 2016;193:438–447.
[57] Houin PR, Deterding RR, Young LR. Exacerbations in neuroendocrine cell hyperplasia of
infancy are characterized by increased air trapping. Pediatr. Pulmonol. 2016;51:E9-12.
[58] Young LR, Brody AS, Inge TH, et al. Neuroendocrine cell distribution and frequency
distinguish neuroendocrine cell hyperplasia of infancy from other pulmonary disorders. Chest.
2011;139:1060–1071.
[59] Yancheva SG, Velani A, Rice A, et al. Bombesin staining in neuroendocrine cell hyperplasia
of infancy (NEHI) and other childhood interstitial lung diseases (chILD). Histopathology.
2015;Oct;67(4):501-8
[60] Cutz E, Chami R, Dell S, et al. Pulmonary interstitial glycogenosis associated with a spectrum
of neonatal pulmonary disorders. Hum. Pathol. 2017;68:154–165.
[61] Langston C, Dishop MK. Diffuse lung disease in infancy: a proposed classification applied to
259 diagnostic biopsies. Pediatr. Dev. Pathol. 2009;12:421–437.
t
[62] Szafranski P, Coban-Akdemir ZH, Rupps R, et al. Phenotypic expansion of TBX4 mutations
ip
to include acinar dysplasia of the lungs. Am. J. Med. Genet. A. 2016;170:2440–2444.
[63] Barnett CP, Nataren NJ, Klingler-Hoffmann M, et al. Ectrodactyly and Lethal Pulmonary
cr
Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing.
Hum. Mutat. 2016;37:955–963.
us
[64] Stankiewicz P, Sen P, Bhatt SS, et al. Genomic and genic deletions of the FOX gene cluster on
16q24.1 and inactivating mutations of FOXF1 cause alveolar capillary dysplasia and other
malformations. Am. J. Hum. Genet. 2009;84:780–791.
an
[65] Szafranski P, Dharmadhikari AV, Wambach JA, et al. Two deletions overlapping a distant
FOXF1 enhancer unravel the role of lncRNA LINC01081 in etiology of alveolar capillary dysplasia
with misalignment of pulmonary veins. Am. J. Med. Genet. A. 2014;164A:2013–2019.
M
[66] Slot E, Edel G, Cutz E, et al. Alveolar capillary dysplasia with misalignment of the pulmonary
veins: clinical, histological, and genetic aspects. Pulm Circ. 2018;8:2045894018795143.
ed
[67] Lange M, Kasper B, Bohring A, et al. 47 patients with FLNA associated periventricular
nodular heterotopia. Orphanet J Rare Dis. 2015;10:134.
[68] Shelmerdine SC, Semple T, Wallis C, et al. Filamin A (FLNA) mutation-A newcomer to the
pt
[69] Nathan N, Borensztajn K, Clement A. Genetic causes and clinical management of pediatric
ce
[70] * Gupta A, Zheng SL. Genetic disorders of surfactant protein dysfunction: when to consider
Ac
The authors reviewed the current knowledge on surfactant disorders in children, mainly in relation
with SP-B, SP-C, ABCA3 and NKX2-1 deficiencies: clinical presentation, investigations,
management.
[71] Litao MKS, Hayes D, Chiwane S, et al. A novel surfactant protein C gene mutation associated
with progressive respiratory failure in infancy. Pediatr. Pulmonol. 2017;52:57–68.
[72] Delestrain C, Simon S, Aissat A, et al. Deciphering the mechanism of Q145H SFTPC
mutation unmasks a splicing defect and explains the severity of the phenotype. Eur. J. Hum. Genet.
2017;25:779–782.
[73] * Salerno T, Peca D, Menchini L, et al. Surfactant Protein C-associated interstitial lung
disease; three different phenotypes of the same SFTPC mutation. Ital J Pediatr. 2016;42:23.
An article that reinforces the knowledge that the most frequent mutation of SFTPC, I73T, is associated
with a highly variable phenotype.
[74] Hawkins A, Guttentag SH, Deterding R, et al. A non-BRICHOS SFTPC mutant (SP-CI73T)
linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular
proteostasis and mitophagy. Am. J. Physiol. Lung Cell Mol. Physiol. 2015;308:L33-47.
[75] Avital A, Hevroni A, Godfrey S, et al. Natural history of five children with surfactant protein
t
C mutations and interstitial lung disease. Pediatr. Pulmonol. 2014;49:1097–1105.
ip
[76] Abou Taam R, Jaubert F, Emond S, et al. Familial interstitial disease with I73T mutation: A
mid- and long-term study. Pediatr Pulmonol. 2009;44:167–175.
cr
[77] Shulenin S, Nogee LM, Annilo T, et al. ABCA3 gene mutations in newborns with fatal
us
surfactant deficiency. N Engl J Med. 2004;350:1296–1303.
[78] Zhou W, Zhuang Y, Sun J, et al. Variants of the ABCA3 gene might contribute to
susceptibility to interstitial lung diseases in the Chinese population. Sci Rep. 2017;7:4097.
an
[79] Campo I, Zorzetto M, Mariani F, et al. A large kindred of pulmonary fibrosis associated with a
novel ABCA3 gene variant. Respir. Res. 2014;15:43.
M
[80] * Kröner C, Wittmann T, Reu S, et al. Lung disease caused by ABCA3 mutations. Thorax.
2017;72:213–220.
The authors reported a large population of patients with ABCA3 mutations, with information on
ed
[81] Thavagnanam S, Cutz E, Manson D, et al. Variable clinical outcome of ABCA3 deficiency in
pt
[82] Wambach JA, Wegner DJ, Depass K, et al. Single ABCA3 mutations increase risk for
ce
[83] Devriendt K, Vanhole C, Matthijs G, et al. Deletion of thyroid transcription factor-1 gene in an
infant with neonatal thyroid dysfunction and respiratory failure. N Engl J Med. 1998;338:1317–1318.
Ac
[84] Hamvas A, Deterding RR, Wert SE, et al. Heterogeneous pulmonary phenotypes associated
with mutations in the thyroid transcription factor gene NKX2-1. Chest. 2013;144:794–804.
[85] * Nattes E, Lejeune S, Carsin A, et al. Heterogeneity of lung disease associated with NK2
homeobox 1 mutations. Respir Med. 2017;129:16–23.
The authors presented a large cohort of patients with NKX2-1 mutations with description of disease
expression.
[86] Nogee LM, de Mello DE, Dehner LP, et al. Brief report: deficiency of pulmonary surfactant
protein B in congenital alveolar proteinosis. N Engl J Med. 1993;328:406–410.
[87] Nathan N, Taam RA, Epaud R, et al. A national internet-linked based database for pediatric
interstitial lung diseases: the French network. Orphanet J. Rare Dis. 2012;7:40.
[88] Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene
responsible for fatal neonatal respiratory disease in multiple kindreds. J. Clin. Invest. 1994;93:1860–
1863.
[89] Hoover RR, Floros J. Organization of the human SP-A and SP-D loci at 10q22-q23. Physical
and radiation hybrid mapping reveal gene order and orientation. American Journal of Respiratory Cell
and Molecular Biology. 1998;18:353–362.
[90] Silveyra P, Floros J. Genetic complexity of the human surfactant-associated proteins SP-A1
t
and SP-A2. Gene. 2013;531:126–132.
ip
[91] Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with
cr
pulmonary fibrosis and lung cancer. American Journal of Human Genetics. 2009;84:52–59.
[92] Coghlan MA, Shifren A, Huang HJ, et al. Sequencing of idiopathic pulmonary fibrosis-related
us
genes reveals independent single gene associations. BMJ Open Respir Res. 2014;1:e000057.
[93] van Moorsel CHM, Ten Klooster L, van Oosterhout MFM, et al. SFTPA2 Mutations in
Familial and Sporadic Idiopathic Interstitial Pneumonia. Am. J. Respir. Crit. Care Med.
an
2015;192:1249–1252.
[94] * Nathan N, Giraud V, Picard C, et al. Germline SFTPA1 mutation in familial idiopathic
interstitial pneumonia and lung cancer. Hum. Mol. Genet. 2016;25:1457–1467.
M
In this article, we reported the first description of a pathogenic SFTPA1 mutation associated with
various forms of interstitial pneumonia or lung fibrosis and adenocarcinoma of the lung. The mutation
was found in a large family that included both children and adults patients.
ed
Genet. 2015;96:826–831.
[96] Hildebrandt J, Yalcin E, Bresser H-G, et al. Characterization of CSF2RA mutation related
ce
[97] Suzuki T, Maranda B, Sakagami T, et al. Hereditary pulmonary alveolar proteinosis caused by
Ac
[98] * Tarantino G, Esposito S, Andreozzi L, et al. Lung Involvement in Children with Hereditary
Autoinflammatory Disorders. Int J Mol Sci. 2016;17.
The article was a review on autoinflammatory diseases with a lung involvement, including SAVI (due
to TMEM173 mutations), and COPA syndrome.
[99] Melki I, Rose Y, Uggenti C, et al. Disease-associated mutations identify a novel region in
human STING necessary for the control of type I interferon signaling. J. Allergy Clin. Immunol.
2017;140:543-552.e5.
[100] Picard C, Thouvenin G, Kannengiesser C, et al. Severe Pulmonary Fibrosis as the First
Manifestation of Interferonopathy (TMEM173 Mutation). Chest. 2016;150:e65-71.
[102] Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome.
N. Engl. J. Med. 2014;371:507–518.
[103] ** Watkin LB, Jessen B, Wiszniewski W, et al. COPA mutations impair ER-Golgi transport
and cause hereditary autoimmune-mediated lung disease and arthritis. Nat. Genet. 2015;47:654–660.
t
The authors described a new autoinflammatory disorder due to COPA mutations. All of the described
ip
patients presented a lung involvement with ILD or hemosiderosis.
cr
[104] Jensson BO, Hansdottir S, Arnadottir GA, et al. COPA syndrome in an Icelandic family
caused by a recurrent missense mutation in COPA. BMC Med. Genet. 2017;18:129.
us
[105] Vece TJ, Watkin LB, Nicholas S, et al. Copa Syndrome: a Novel Autosomal Dominant
Immune Dysregulatory Disease. J. Clin. Immunol. 2016;36:377–387.
an
[106] Nathan N, Borie R, Kannengiesser C, et al. Genetic testing in idiopathic interstitial
pneumonia. 2016;PA4849
[107] Brown AW, Kaya H, Nathan SD. Lung transplantation in IIP: A review. Respirology. 2016
M
Oct;21(7):1173-84
[108] Eldridge WB, Zhang Q, Faro A, et al. Outcomes of Lung Transplantation for Infants and
Children with Genetic Disorders of Surfactant Metabolism. J. Pediatr. 2017;184:157-164.e2.
ed
pt
ce
Ac
Table 1: Diagnosis approaches of pediatric ILD
ILD related to ILD related to systemic ILD related to lung ILD specific to infancy
exposure/environment diseases processes primary parenchyma
insults dysfunctions
Hypersensitivity Connective tissue Surfactant disorders Neuroendocrine cell
pneumonitis diseases hyperplasia of infancy
Medication, Drugs Vasculitis Diffuse alveolar Pulmonary interstitial
Radiation exposure hemorrhages glycogenosis
Granulomatous Eosinophilic lung Diffuse developmental
t
disorders diseases disorders
ip
Metabolic disorders Lymphatic disorders
cr
Viral infections
us
an
M
ed
pt
ce
Ac